Pub Date : 2019-01-01DOI: 10.1007/978-3-319-72303-7_27
J. Thoppay, A. Filippi, Katharine Ciarrocca, John Greenman, S. D. De Rossi
{"title":"Halitosis.","authors":"J. Thoppay, A. Filippi, Katharine Ciarrocca, John Greenman, S. D. De Rossi","doi":"10.1007/978-3-319-72303-7_27","DOIUrl":"https://doi.org/10.1007/978-3-319-72303-7_27","url":null,"abstract":"","PeriodicalId":22419,"journal":{"name":"The Indian practitioner","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87301768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-28DOI: 10.1002/9781118829875.ch13
M. Karvonen
{"title":"Diet and cardiovascular disease.","authors":"M. Karvonen","doi":"10.1002/9781118829875.ch13","DOIUrl":"https://doi.org/10.1002/9781118829875.ch13","url":null,"abstract":"","PeriodicalId":22419,"journal":{"name":"The Indian practitioner","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88757191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-08-01DOI: 10.1093/med/9780199568741.003.0051
S. Saeed, R. Ramsden
Hearing loss must be divided into conductive hearing loss (CHL) and sensorineural hearing loss (SNHL). CHL is caused by sound not reaching the cochlear (abnormality of the ear canal, tympanic membrane, middle ear, or ossicles), whereas SNHL is a condition affecting the cochlear or auditory (eighth cranial) nerve. Hearing loss may be accompanied by other cardinal signs of ear disease, such as pain or discharge from the ear, vertigo, facial nerve palsy, and tinnitus, which guide the diagnosis. This chapter describes the approach to the patient with hearing loss.
{"title":"Hearing loss.","authors":"S. Saeed, R. Ramsden","doi":"10.1093/med/9780199568741.003.0051","DOIUrl":"https://doi.org/10.1093/med/9780199568741.003.0051","url":null,"abstract":"Hearing loss must be divided into conductive hearing loss (CHL) and sensorineural hearing loss (SNHL). CHL is caused by sound not reaching the cochlear (abnormality of the ear canal, tympanic membrane, middle ear, or ossicles), whereas SNHL is a condition affecting the cochlear or auditory (eighth cranial) nerve. Hearing loss may be accompanied by other cardinal signs of ear disease, such as pain or discharge from the ear, vertigo, facial nerve palsy, and tinnitus, which guide the diagnosis. This chapter describes the approach to the patient with hearing loss.","PeriodicalId":22419,"journal":{"name":"The Indian practitioner","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84837815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-08-01DOI: 10.12781/978-1-907549-32-8-2
Erik Amnå, D. Sachs
Many Western democracies have lately become the object of a wide-spread populistic critique. They are severely marked by increasing social and economic inequality that spills over into democratic i ...
{"title":"Translating Civic Engagement into Political Participation : A Non-partisan School for Becoming a Politician","authors":"Erik Amnå, D. Sachs","doi":"10.12781/978-1-907549-32-8-2","DOIUrl":"https://doi.org/10.12781/978-1-907549-32-8-2","url":null,"abstract":"Many Western democracies have lately become the object of a wide-spread populistic critique. They are severely marked by increasing social and economic inequality that spills over into democratic i ...","PeriodicalId":22419,"journal":{"name":"The Indian practitioner","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81833065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-02-01DOI: 10.22376/IJPBS.2017.8.2.P163-178
M. Kiran, H. Chandalia
Teneligliptin is the newest DPP4 inhibitor approved by the regulatory authority for the treatment of Diabetes mellitus. Teneligliptin scores over other 'gliptins' in being more economical and with better efficacy to control blood glucose and HbA1C levels. Teneligliptin additionally offers other pharmacological advantages like longer half-life, lesser IC50 value, tight and extensive binding to the DPP4 enzyme. Teneligliptin has been studies extensively for its safety and efficacy in various clinical trials conducted internationally. This review article comprehensively documents the available clinical and pharmacological data for Teneligliptin in the treatment of Diabetes mellitus.
{"title":"Teneligliptin – The Newest DPP4 Inhibitor","authors":"M. Kiran, H. Chandalia","doi":"10.22376/IJPBS.2017.8.2.P163-178","DOIUrl":"https://doi.org/10.22376/IJPBS.2017.8.2.P163-178","url":null,"abstract":"Teneligliptin is the newest DPP4 inhibitor approved by the regulatory authority for the treatment of Diabetes mellitus. Teneligliptin scores over other 'gliptins' in being more economical and with better efficacy to control blood glucose and HbA1C levels. Teneligliptin additionally offers other pharmacological advantages like longer half-life, lesser IC50 value, tight and extensive binding to the DPP4 enzyme. Teneligliptin has been studies extensively for its safety and efficacy in various clinical trials conducted internationally. This review article comprehensively documents the available clinical and pharmacological data for Teneligliptin in the treatment of Diabetes mellitus.","PeriodicalId":22419,"journal":{"name":"The Indian practitioner","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75857762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-09-01DOI: 10.1097/00152193-197905000-00019
N. Stollery
{"title":"Conditions in children.","authors":"N. Stollery","doi":"10.1097/00152193-197905000-00019","DOIUrl":"https://doi.org/10.1097/00152193-197905000-00019","url":null,"abstract":"","PeriodicalId":22419,"journal":{"name":"The Indian practitioner","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2014-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89655178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：